Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody

NEXT STORY
Immunicum tillkännager deltagande i flera kommande bransch- och investerarmöten i september och oktober
PREV STORY
CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board

CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology ...

author_avatar
NASDAQ Market News

RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection

author_avatar
NASDAQ Market News

T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indications

author_avatar
NASDAQ Market News